doi: 10.1002/alz.12088 46 BabaeiP
In: Feldman: Sleisenger and Fordtrans Gastrointestinal and Liver Disease, 9th ed
PeptideComfort was crafted with the input of healthcare professionals to ensure the highest efficacy for individuals undergoing GLP-1 and GIP therapy
The state obesity drug coverage landscape will continue to evolve as states respond to the recent announcement of the BALANCE model (see Box 1) and as states contend with budget challenges and the federal Medicaid spending cuts in the 2025 reconciliation law
49 In another phase 1 study conducted in 37 Japanese patients, the most common treatment-related side effects were nausea, vomiting, abdominal discomfort, diarrhea, and headache, mostly mild to moderate in severity
Everyone responds differently, so tracking the impact after dose adjustments is key